A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies - Holida, M; Linhart, A; Pisani, A (J Inherit Metab Dis, 2025)
et al.